A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: Evidence for dysregulated expression of JUNB and JUND in MF and SS

Journal of Cutaneous Pathology

Volumn 35, Issue 10, 2008, Pages 899-910

  Mao, Xin ^a   Orchard, Guy ^a   Mitchell, Tracey J ^a   Oyama, Noritaka ^a   Russell Jones, Robin ^a   Vermeer, Maarten H ^c   Willemze, Rein ^c   Van Doorn, Remko ^c   Tensen, Cornelis P ^c   Young, Bryan D ^b   Whittaker, Sean J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MYCOSIS FUNGOIDES; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEZARY SYNDROME;

GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MITOGEN-ACTIVATED PROTEIN KINASES; MYCOSIS FUNGOIDES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-JUN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEZARY SYNDROME; SKIN NEOPLASMS; TRANSCRIPTION FACTOR AP-1;

EID: 51649122809     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2007.00924.x     Document Type: Article

References (54)

1. Chinenov Y, Kerppola TK. Close encounters of many kinds: fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 2001 20 : 2438.
2. Vogt PK. Fortuitous convergences: the beginnings of JUN. Nature Rev Cancer 2002 2 : 465.
3. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003 3 : 859.
4. Chiu R, Angel P, Karin M. Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell 1989 59 : 979.
5. Deng T, Karin M. JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. Genes Dev 1993 7 : 479.
6. Pfarr CM, Mechta F, Spyrou G, Lallemand D, Carillo S, Yaniv M. Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras. Cell 1994 76 : 747.
7. Agarwal SK, Guru SC, Heppner C, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999 96 : 143.
8. Thepot D, Weitzman JB, Barra J, et al. Targeted disruption of the murine junD gene results in multiple defects in male reproductive function. Development 2000 127 : 143.
9. Passegue E, Jochum W, Schorpp-Kistner M, Mohle-Steinlein U, Wagner EF. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 2001 104 : 21.
10. Zenz R, Scheuch H, Martin P, et al. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell 2003 4 : 879.
11. Kari L, Loboda A, Nebozhyn M, et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003 197 : 1477.
12. Mao X, Orchard G, Lillington D, Russell-Jones R, Young B, Whittaker S. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 2003 101 : 1513.
13. Mao X, Lillington D, Scarisbrick J, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. Br J Dematol 2002 147 : 464.
14. Szremska AP, Kenner L, Weisz E, et al. JunB inhibits proliferation and transformation in B-lymphoid cells. Blood 2003 102 : 4159.
15. Watanabe M, Ogawa Y, Ito K, et al. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells. Am J Pathol 2003 163 : 633.
16. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker S. Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. Genes Chromosomes Cancer 2003 37 : 176.
17. Mao X, Orchard G, Lillington D, et al. BCL2 and JUNB abnormalities in primary cutaneous lymphomas. Br J Dematol 2004 151 : 546.
18. Orchard GE. Immunohistochemical techniques in dermatopathology. Biomed Scientist 2004 48 : 695.
19. van Doorn R, Dijkman R, Vermeer MH, et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res 2004 64 : 5578.
20. Mitchell TJ, Whittaker SJ, John S. Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary syndrome. Cancer Res 2003 63 : 9048.
21. Mao X, Lillington D, Czepulkowski B, Russell-Jones R, Young B, Whittaker S. Molecular cytogenetic characterisation of Sezary syndrome. Genes Chromosomes Cancer 2003 36 : 250.
22. McDaid HM, Lopez-Barcons L, Grossman A, et al. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res 2005 65 : 2854.
23. Qin JZ, Dummer R, Burg G, Dobbeling U. Constitutive and interleukin-7/interleukin-15 stimulated DNA binding of Myc, Jun, and novel Myc-like proteins in cutaneous T-cell lymphoma cells. Blood 1999 93 : 260.
24. Angel P, Szabowski A, Schorpp-Kistner M. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 2001 20 : 2413.
25. Herdegen T, Waetzig V. AP-1 proteins in the adult brain: facts and fiction about effectors of neuroprotection and neurodegeneration. Oncogene 2001 20 : 2424.
26. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001 20 : 2401.
27. Rittie L, Fisher GJ. UV-light-induced signal cascades and skin aging. Ageing Res Rev 2002 1 : 705.
28. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001 20 : 2390.
29. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002 4 : E131.
30. Eferl R, Ricci R, Kenner L, et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 2003 112 : 181.
31. Finch S, Joseloff E, Bowden T. JunB negatively regulates AP-1 activity and cell proliferation of malignant mouse keratinocytes. J Cancer Res Clin Oncol 2002 128 : 3.
32. Weitzman JB. Juggling jun. Nat Genet 2002 30 : 158.
33. Passegue E, Jochum W, Behrens A, Ricci R, Wagner EF. JunB can substitute for Jun in mouse development and cell proliferation. Nat Genet 2002 30 : 158.
34. Crossen PE. Genes and chromosomes in chronic B-cell leukemia. Cancer Genet Cytogenet 1997 94 : 44.
35. Rimokh R, Berger F, Delsol G, et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood 1994 83 : 1871.
36. Mao X, Orchard G, Vonderheid EC, et al. Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-cell lymphomas suggesting impaired cell cycle control in disease pathogenesis. J Invest Dermatol 2006 126 : 1388.
37. Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002 21 : 4104.
38. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997 90 : 354.
39. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005 105 : 3768.
40. Watanabe M, Sasaki M, Itoh K, et al. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res 2005 65 : 7628.
41. Rooney JW, Hodge MR, McCaffrey PG, Rao A, Glimcher LH. A common factor regulates both Th1- and Th2-specific cytokine gene expression. EMBO J 1994 13 : 625.
42. Rincon M, Derijard B, Chow CW, Davis RJ, Flavell RA. Reprogramming the signalling requirement for AP-1 (activator protein-1) activation during differentiation of precursor CD4+ T-cells into effector Th1 and Th2 cells. Genes Funct 1997 1 : 51.
43. Yang DD, Conze D, Whitmarsh AJ, et al. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998 9 : 575.
44. Cerdan C, Serfling E, Olive D. The C-class chemokine, lymphotactin, impairs the induction of Th1-type lymphokines in human CD4(+) T cells. Blood 2000 96 : 420.
45. Lavender P, Cousins D, Lee T. Regulation of Th2 cytokine gene transcription. Chem Immunol 2000 78 : 16.
46. Schwenger GT, Kok CC, Arthaningtyas E, Thomas MA, Sanderson CJ, Mordvinov VA. Specific activation of human interleukin-5 depends on de novo synthesis of an AP-1 complex. J Biol Chem 2002 277 : 47022.
47. Zhang J, Salojin KV, Gao JX, Cameron MJ, Bergerot I, Delovitch TL. p38 mitogen-activated protein kinase mediates signal integration of TCR/CD28 costimulation in primary murine T cells. J Immunol 1999 162 : 3819.
48. Serfling E, Berberich-Siebelt F, Chuvpilo S, et al. The role of NF-AT transcription factors in T cell activation and differentiation. Biochim Biophys Acta 2000 1498 : 1.
49. Conze D, Krahl T, Kennedy N, et al. c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation. J Exp Med 2002 195 : 811.
50. Fortin JF, Barat C, Beausejour Y, Barbeau B, Tremblay MJ. Hyper-responsiveness to stimulation of human immunodeficiency virus-infected CD4+ T cells requires Nef and Tat virus gene products and results from higher NFAT, NF-kappaB, and AP-1 induction. J Biol Chem 2004 279 : 39520.
51. Humar M, Andriopoulos N, Pischke SE, et al. Inhibition of AP-1 by barbiturates is mediated by differential effects on MAP-kinases and the small G proteins Ras and Rac-1. J Pharmacol Exp Ther 2004 311 : 1232.
52. Tsitoura DC, Rothman PB. Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells. J Clin Invest 2004 113 : 619.
53. Li B, Tournier C, Davis RJ, Flavell RA. Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation. EMBO J 1999 18 : 420.
54. Voice J, Donnelly S, Dorsam G, Dolganov G, Paul S, Goetzl EJ. c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J Immunol 2004 172 : 7289.